{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:39:11Z","timestamp":1792809551198,"version":"4.5.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Plasma teicoplanin concentrations do not reach the therapeutic range in several patients with hematological malignancies. Nevertheless, the characteristics of the population pharmacokinetic (PPK) models have not been clarified for malignancy. The decrease in the teicoplanin concentration in patients with cancer has been attributed to augmented renal clearance (ARC). It is essential to identify the causative factors of ARC to construct a PPK model to optimize the administration method. The authors aimed to establish a PPK model and develop an appropriate dosing regimen for teicoplanin in patients with hematological malignancies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PPK analysis was performed using therapeutic drug monitoring (TDM) data from 119 patients with hematological malignancies. The developed model was verified by predictive performance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The covariates affecting systemic clearance were serum creatinine, presence or absence of neutropenia (&lt;500\/\u03bcL), and body size descriptor. Patients with hematologic malignancies and neutropenia showed a 25% increase in clearance compared with those with a normal neutrophil count. The PPK model was constructed based on the presence or absence of neutropenia. This model allowed the selection of the most appropriate dosage regimen out of those recommended by the TDM guidelines for patients with eGFR of &gt;60 mL\/min\/1.73 m<jats:sup>2<\/jats:sup>. The PPK model predicted a dosing regimen for achieving a 10% improvement in the coverage probability of the target concentration range during the loading and maintenance phases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The PPK model may help optimize dose regimens and evaluate dosing methods, using comparative simulations, in patients with hematological malignancies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000906","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T11:00:10Z","timestamp":1626087610000},"page":"519-526","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Population Pharmacokinetics of Teicoplanin and Its Dosing Recommendations for Neutropenic Patients With Augmented Renal Clearance for Hematological Malignancies"],"prefix":"10.1097","volume":"43","author":[{"given":"Ken-ichi","family":"Sako","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan;"},{"name":"Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Nakamaru","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuro","family":"Ikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoji","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kato","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1128\/AAC.40.5.1242","article-title":"Population pharmacokinetic study of teicoplanin in severely neutropenic patients","volume":"40","author":"Lortholary","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1128\/AAC.42.4.849","article-title":"Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults","volume":"42","author":"Tod","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nrneph.2011.92","article-title":"Implications of augmented renal clearance in critically ill patients","volume":"7","author":"Udy","year":"2011","journal-title":"Nat Rev Nephrol."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"227","DOI":"10.7326\/0003-4819-113-3-227","article-title":"Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy","volume":"113","author":"Parrillo","year":"1990","journal-title":"Ann Intern Med."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00003246-198002000-00004","article-title":"Renal function in critically ill postoperative patients","volume":"8","author":"Brown","year":"1980","journal-title":"Crit Care Med."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1378\/chest.124.3.1053","article-title":"Vital organ blood flow during hyperdynamic sepsis","volume":"124","author":"Giantomasso","year":"2003","journal-title":"Chest"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient\u2014concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv Drug Deliver Rev."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1007\/s00134-002-1444-x","article-title":"Norepinephrine and vital organ blood flow","volume":"28","author":"Giantomasso","year":"2002","journal-title":"Intens Care Med."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-200039030-00001","article-title":"Clinical pharmacokinetics of teicoplanin","volume":"39","author":"Wilson","year":"2000","journal-title":"Clin Pharmacokinet."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.35.3.451","article-title":"Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts","volume":"35","author":"Auwera","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00341-09","article-title":"Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis","volume":"53","author":"Svetitsky","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20250603","first-page":"1","article-title":"Population pharmacokinetics of teicoplanin in adult patients","volume":"54","author":"Nakayama","year":"2006","journal-title":"Jpn J Chemother."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5414\/CP201739","article-title":"Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection","volume":"51","author":"Ogawa","year":"2013","journal-title":"Int J Clin Pharmacol Ther."},{"key":"R15-20250603","first-page":"188","article-title":"Population pharmacokinetics analysis of generic teicoplanin with MRSA or GPC infection by multicenter study","volume":"32","author":"Tsuji","year":"2015","journal-title":"Jpn J TDM"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.2011.04080.x","article-title":"TDM guidelines for antibiotics","volume":"73","author":"Roberts","year":"2012","journal-title":"Br J Clin Pharmacol."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1758-8111.2012.00039.x","article-title":"Plasma amino acid profile is associated with visceral fat accumulation in obese Japanese subjects","volume":"2","author":"Yamakado","year":"2012","journal-title":"Clin Obes."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:12:32Z","timestamp":1748970752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000906","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"2021-01-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}